Balversa (erdafitinib) — Medica
Urothelial carcinoma
Initial criteria
- age ≥ 18 years
- has locally advanced or metastatic disease
- has susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations
- has progressed during or following prior platinum-containing chemotherapy, other chemotherapy, or checkpoint inhibitor therapy
- used as a single agent
Approval duration
1 year